Treatments for lung damage from phosgene gas
Identification and optimization of medical countermeasures for phosgene inhalation injuries
This project develops drug approaches to protect and treat lungs after phosgene gas inhalation, aimed at people who suffer severe lung injury from such exposures.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11170627 on NIH RePORTER |
What this research studies
Researchers are testing whether existing blood-pressure drugs called ACE inhibitors and experimental drugs called soluble epoxide hydrolase (sEH) inhibitors can reduce lung swelling and inflammation caused by phosgene gas. They use laboratory experiments and animal models to measure survival, fluid leak into the lungs, and inflammatory cell counts while refining doses and timing. The team will optimize drug combinations or formulations that show the best protection and recovery of lung function. If results look promising, this preclinical work could guide future clinical trials to treat people after accidental or intentional phosgene inhalation.
Who could benefit from this research
Good fit: People who have inhaled phosgene and developed acute lung injury or ARDS would be the ideal candidates for these countermeasures.
Not a fit: People with chronic lung diseases unrelated to acute chemical inhalation, or those exposed to different toxic gases, may not benefit from these specific treatments.
Why it matters
Potential benefit: If successful, these treatments could lower lung swelling, improve breathing, and reduce deaths after phosgene inhalation.
How similar studies have performed: Prior animal studies show ACE inhibitors and sEH inhibitors can improve survival and reduce lung injury in phosgene and ARDS models, but human effectiveness remains unproven.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Achanta, Satyanarayana — Duke University
- Study coordinator: Achanta, Satyanarayana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.